FILE PHOTO: Lilly Biotechnology Center is shown in San Diego, California, U.S. March 1, 2023 after Eli Lilly and Co on Wednesday said it will cut list prices by 70% for its most commonly prescribed insulin products, Humalog and Humulin, beginning from the fourth quarter of this year. REUTERS/Mike Blake/File Photo
